{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:10:15Z","timestamp":1779289815501,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jjcc.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T11:35:26Z","timestamp":1415273726000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antiplatelet therapy after drug-eluting stent implantation"],"prefix":"10.1016","volume":"65","author":[{"given":"Josephine","family":"Warren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Baber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jjcc.2014.10.006_bib0005","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/CIR.0b013e31823a5596","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"issue":"May (17)","key":"10.1016\/j.jjcc.2014.10.006_bib0010","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1161\/01.CIR.0000163587.36485.A7","article-title":"Molecular basis of restenosis and drug-eluting stents","volume":"111","author":"Costa","year":"2005","journal-title":"Circulation"},{"issue":"October (14)","key":"10.1016\/j.jjcc.2014.10.006_bib0015","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"issue":"April (16)","key":"10.1016\/j.jjcc.2014.10.006_bib0020","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/01.CIR.0000127110.49192.72","article-title":"One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial","volume":"109","author":"Stone","year":"2004","journal-title":"Circulation"},{"issue":"October (15)","key":"10.1016\/j.jjcc.2014.10.006_bib0025","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials","volume":"58","author":"Baber","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"May (18)","key":"10.1016\/j.jjcc.2014.10.006_bib0030","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2014.10.006_bib0035","author":"Windecker","year":"2014","journal-title":"EuroInterv"},{"key":"10.1016\/j.jjcc.2014.10.006_bib0040","series-title":"NICE technology appraisal guidance","first-page":"152","article-title":"Coronary artery disease \u2013 drug-eluting stents","author":"Excellence NIfHaC","year":"2008"},{"issue":"February (8)","key":"10.1016\/j.jjcc.2014.10.006_bib0045","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/CIRCULATIONAHA.106.675934","article-title":"Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications","volume":"115","author":"L\u00fcscher","year":"2007","journal-title":"Circulation"},{"issue":"March (10)","key":"10.1016\/j.jjcc.2014.10.006_bib0050","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N Engl J Med"},{"issue":"November (23)","key":"10.1016\/j.jjcc.2014.10.006_bib0055","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2010.07.028","article-title":"In-stent restenosis in the drug-eluting stent era","volume":"56","author":"Dangas","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jjcc.2014.10.006_bib0060","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.ahj.2005.08.011","article-title":"Bare metal stent restenosis is not a benign clinical entity","volume":"151","author":"Chen","year":"2006","journal-title":"Am Heart J"},{"issue":"September (9591)","key":"10.1016\/j.jjcc.2014.10.006_bib0065","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis","volume":"370","author":"Stettler","year":"2007","journal-title":"Lancet"},{"issue":"9562","key":"10.1016\/j.jjcc.2014.10.006_bib0075","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jjcc.2014.10.006_bib0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacc.2013.09.061","article-title":"Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stentsevidence from a comprehensive network meta-analysis","volume":"63","author":"Palmerini","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jjcc.2014.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"June (3)","key":"10.1016\/j.jjcc.2014.10.006_bib0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCINTERVENTIONS.111.967463","article-title":"Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI\/CABG Registry Cohort-2","volume":"5","author":"Tada","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"January (7329)","key":"10.1016\/j.jjcc.2014.10.006_bib0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"January (6921)","key":"10.1016\/j.jjcc.2014.10.006_bib0105","first-page":"81","article-title":"Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration","volume":"308","author":"Therapy Coortoa","year":"1994","journal-title":"BMJ"},{"issue":"9281","key":"10.1016\/j.jjcc.2014.10.006_bib0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"November (19)","key":"10.1016\/j.jjcc.2014.10.006_bib0115","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"June (23)","key":"10.1016\/j.jjcc.2014.10.006_bib0120","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jjcc.2014.10.006_bib0125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"October (16)","key":"10.1016\/j.jjcc.2014.10.006_bib0130","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jjcc.2014.10.006_bib0135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2014.10.006_bib0140","series-title":"Abbott's XIENCE PRIME\u2122 and XIENCE V\u00ae drug eluting stents receive indication in Europe for minimum three-month duration of dual anti-platelet therapy: Abbott Vascular","author":"Abbott Vascular","year":"2012"},{"issue":"November (22)","key":"10.1016\/j.jjcc.2014.10.006_bib0145","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","article-title":"Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period","volume":"30","author":"Schulz","year":"2009","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.jjcc.2014.10.006_bib0150","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"April (16)","key":"10.1016\/j.jjcc.2014.10.006_bib0155","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"issue":"January (3)","key":"10.1016\/j.jjcc.2014.10.006_bib0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"October (15)","key":"10.1016\/j.jjcc.2014.10.006_bib0165","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"July (2)","key":"10.1016\/j.jjcc.2014.10.006_bib0170","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.amjcard.2014.04.035","article-title":"Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents","volume":"114","author":"El-Hayek","year":"2014","journal-title":"Am J Cardiol"},{"issue":"December (24)","key":"10.1016\/j.jjcc.2014.10.006_bib0175","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehs318","article-title":"Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials","volume":"33","author":"Cassese","year":"2012","journal-title":"Eur Heart J"},{"issue":"April (15)","key":"10.1016\/j.jjcc.2014.10.006_bib0185","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"issue":"January (3)","key":"10.1016\/j.jjcc.2014.10.006_bib0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"issue":"December (6)","key":"10.1016\/j.jjcc.2014.10.006_bib0195","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"Mauri","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2014.10.006_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1745-6215-14-56","article-title":"Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial","volume":"14","author":"Helft","year":"2013","journal-title":"Trials"},{"issue":"April (4)","key":"10.1016\/j.jjcc.2014.10.006_bib0205","volume":"157","author":"Byrne","year":"2009","journal-title":"Am Heart J"},{"issue":"March (12)","key":"10.1016\/j.jjcc.2014.10.006_bib0210","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"issue":"December (23)","key":"10.1016\/j.jjcc.2014.10.006_bib0215","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"April (15)","key":"10.1016\/j.jjcc.2014.10.006_bib0220","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/eurheartj\/eht438","article-title":"Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome","volume":"35","author":"Varenhorst","year":"2014","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jjcc.2014.10.006_bib0225","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"issue":"October (15)","key":"10.1016\/j.jjcc.2014.10.006_bib0230","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCULATIONAHA.113.002114","article-title":"Coronary artery revascularization in patients with diabetes mellitus","volume":"128","author":"Armstrong","year":"2013","journal-title":"Circulation"},{"issue":"October (23)","key":"10.1016\/j.jjcc.2014.10.006_bib0235","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.jacc.2008.01.063","article-title":"Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions","volume":"51","author":"Brar","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"August (8)","key":"10.1016\/j.jjcc.2014.10.006_bib0240","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/CIRCULATIONAHA.111.031070","article-title":"Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus","volume":"124","author":"Stone","year":"2011","journal-title":"Circulation"},{"issue":"May (5)","key":"10.1016\/j.jjcc.2014.10.006_bib0245","first-page":"494","article-title":"Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes","volume":"7","author":"Schoos","year":"2014","journal-title":"JACC: Cardiovasc Interv"},{"issue":"February (6)","key":"10.1016\/j.jjcc.2014.10.006_bib0250","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCULATIONAHA.112.141572","article-title":"A history of stroke\/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease","volume":"127","author":"Ducrocq","year":"2013","journal-title":"Circulation"},{"issue":"9906","key":"10.1016\/j.jjcc.2014.10.006_bib0255","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508714003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508714003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:53:43Z","timestamp":1760273623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508714003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0914508714003049"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2014.10.006","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet therapy after drug-eluting stent implantation","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Japanese College of Cardiology. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}